Genetically Engineered Probiotic Competition

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1915-1916

  Kuehn, Meta J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CIPROFLOXACIN; EPIMERASE; ERYTHROMYCIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GANGLIOSIDE GM1; GLYCOSYLTRANSFERASE; ORAL REHYDRATION SOLUTION; PROBIOTIC AGENT; SHIGA TOXIN; TETRACYCLINE;

BIFIDOBACTERIUM; CAMPYLOBACTER JEJUNI; CHOLERA; DRUG EFFICACY; EDITORIAL; ESCHERICHIA COLI; GENETIC ENGINEERING; GLYCOSYLATION; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOREACTIVITY; LACTOBACILLUS; LIPID METABOLISM; METABOLIC ACIDOSIS; NEISSERIA GONORRHOEAE; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIBRIO CHOLERAE;

EID: 33646337635     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.03.031     Document Type: Editorial

References (12)

1. Focareta A., Paton J.C., Morona R., Cook J., and Paton A.W. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130 (2006) 1688-1695
2. Paton A.W., Jennings M.P., Morona R., Wang H., Focareta A., Roddam L.F., and Paton J.C. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128 (2005) 1219-1228
3. Paton A.W., Morona R., and Paton J.C. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6 (2000) 265-270
4. Horstman A.L., and Kuehn M.J. Bacterial surface association of heat-labile enterotoxin through lipopolysaccharide after secretion via the general secretory pathway. J Biol Chem 277 (2002) 32538-32545
5. Kesty N.C., Mason K.M., Reedy M., Miller S.E., and Kuehn M.J. Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells. EMBO J 23 (2004) 4538-4549
6. Sack D.A., Sack R.B., Nair G.B., and Siddique A.K. Cholera. Lancet 363 (2004) 223-233
7. Lindenbaum J., Greenough W.B., and Islam M.R. Antibiotic therapy of cholera in children. Bull World Health Organ 37 (1967) 529-538
8. Saha D., Khan W.A., Karim M.M., Chowdhury H.R., Salam M.A., and Bennish M.L. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera. a randomised controlled trial. Lancet 366 (2005) 1085-1093
9. Baker M. Better living through microbes. Nat Biotechnol 23 (2005) 645-647
10. Zhang Z., Merritt E.A., Ahn M., Roach C., Hou Z., Verlinde C.L., Hol W.G., and Fan E. Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc 124 (2002) 12991-1298
11. Isolauri E., Kirjavainen P.V., and Salminen S. Probiotics. a role in the treatment of intestinal infection and inflammation?. Gut 50 Suppl 3 (2002) III54-III59
12. Meredith TC, Aggarwal P, Mamat U, Lindner B, Woodard RW. Redefining the requisite lipopolysaccharide structure in Escherichia coli ACS Chemical Biology, 2006. 1: Online January 3, 2006.